Online Reports

Hypervirulent Klebsiella pneumoniae (hvKp) can cause life-threatening infections in healthy community members. HvKp infections often involve multiple sites, some of which are unusual for classical K. pneumoniae (cKp) infections, such as the central nervous system, eyes, and fascia. The acquisition of antimicrobial resistance by hvKp has resulted in concerns of an emerging superbug. This concern is magnified by increasing geographic dissemination and healthcare associated infections. Currently, diagnostic testing to differentiate hvKp from cKp is lacking, causing challenges for clinical care, surveillance, and research. Although imperfect, the detection of all 5 of the biomarkers iucA, iroB, peg-344, rmpA, and rmpA2 is the most accurate and pragmatic means to identify hvKp. We propose a working definition for hvKp that will enhance accuracy for diagnosis and surveillance, which will aid in preventing the spread of hvKp.

Event management systems (EMS) are key tools for epidemic intelligence, integrating surveillance signals and incident response, although international standards to inform development are lacking. We describe the Nigeria Centre for Disease Control and Prevention (NCDC) SITAware, a software capable of operating with low internet bandwidth to generate notifications, reports, and spatiotemporal dashboards and provide event-level data for real-time accountability and postevent learning. SITAware was enabled by local institutional ownership, co-created at low cost, and integrated into existing workflows. In 2022, SITAware was used to manage ≈300 incidents, and NCDC implemented it subnationally. NCDC’s experience may inform EMS development and implementation in similar settings.

Since the severe acute respiratory syndrome outbreak in 2003, China has invested substantial efforts in promoting scientific and technological advances for medical countermeasures against high-threat pathogens. The examination of China’s landscape identifies progress and gaps in research and development (R&D) and also highlights management and regulatory issues that should be of concern to other countries. Our study examined the current state of R&D of medical countermeasures in China during 1990–2022. The findings showed a robust and diversified pipeline responding quickly to disease outbreaks and policy changes. However, proactive and highly innovative candidates are limited, and a large proportion of vaccines and drugs stagnate at the early development stage. A paradigm shift involving a preemptive R&D agenda and persistent investment, innovative technology development, and accelerated research translation is urgently needed to prepare for the next pandemic.